RLD2203(RLD2203) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用机制-

治疗领域-

在研适应症-

非在研适应症-

原研机构

Hanmi Pharmaceutical Co., Ltd.

在研机构

Hanmi Pharmaceutical Co., Ltd.

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 RLD2203 相关的临床试验

NCT05548543

/ Completed临床1期

A Randomized, Open Label, Single Dose, 4-period Replicate Crossover Clinical Trial to Evaluate the Pharmacokinetic Characteristics and Safety After Administration of a Fixed-dose Combination Drug of HCP2202 and Co-administration of RLD2202 and RLD2203 in Healthy Volunteers Under Fed Conditions

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HCP2202 and co-administration of each component in fed condition in healthy volunteers.

开始日期2022-10-17

申办/合作机构

Hanmi Pharmaceutical Co., Ltd.

NCT05548387

/ Completed临床1期

A Randomized, Open Label, Single Dose, 4-period Replicate Crossover Clinical Trial to Evaluate the Pharmacokinetic Characteristics and Safety After Administration of a Fixed-dose Combination Drug of HCP2202 or Co-administration of RLD2202 and RLD2203 in Healthy Volunteers Under Fasting Conditions

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HCP2202 and co-administration of each component in fasting condition in healthy volunteers.

开始日期2022-09-02

申办/合作机构

Hanmi Pharmaceutical Co., Ltd.

NCT05481307

/ Completed临床1期

An Open-label Phase 1 Study to Evaluate PK/PD Drug-drug Interactions and Safety/Tolerability Between RLD2202 and RLD2203 in Healthy Adult Subjects

The purpose of this study is to evaluate pharmacokinetic/pharmacodynamic drug-drug interactions and safety/tolerability between RLD2202 and RLD2203 in healthy adult subjects

开始日期2022-08-02

申办/合作机构

Hanmi Pharmaceutical Co., Ltd.

100 项与 RLD2203 相关的临床结果

登录后查看更多信息

100 项与 RLD2203 相关的转化医学

登录后查看更多信息

100 项与 RLD2203 相关的专利（医药）

登录后查看更多信息

100 项与 RLD2203 相关的药物交易

登录后查看更多信息